pp-139 Concentrate for solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Metastatic castration-resistant prostate cancer (mCRPC); other solid tumours
Clinical stage: Phase 2
Modality: Biologic (bispecific PD-1 × CTLA-4 monoclonal antibody)
Mechanism / Target: Dual checkpoint blockade — simultaneously engages PD-1 and CTLA-4 on T cells, enhancing anti-tumour immune responses via complementary mechanisms
Route / form: Intravenous or subcutaneous injection
Differentiation: Single-molecule dual checkpoint blockade simplifies combination regimen; potential for tumour-localised CTLA-4 blockade if PD-1/CTLA-4 co-expression enriched at tumour site
Manufacturer #39170
Clinical-stage immuno-oncology company advancing STING agonist and bispecific checkpoint therapies. Combines proprietary imaging technology with drug development to characterise immune activity. Wholly owned global rights to late-stage oncology candidates.
None